In the aspect of immunotherapy efficacy, although anti‐PD‐1 monotherapy could partly decrease tumor burden, cotreatment of BCAT2 KD and anti‐PD‐1 monoclonal antibody (mab) indicated a better tumor suppression effect and gained more survival benefit. This evidence concerns the gene BCAT2 and neoplasm.